1910 Genetics

1910 Genetics is a biotechnology startup with a mission to revolutionize drug discovery using advanced AI and laboratory automation. Their slogan, "Advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation," succinctly captures their core focus. Founded in 2018 and headquartered in the United States, the company has gained significant attention in the industry for its innovative approach. The startup stands out for its unique integration of AI with three proprietary data streams - computational data, wet lab proxy biological data, and wet lab ground truth biological data. This integration enables the delivery of novel drug candidates and software solutions to leading pharma and tech partners. Their internal pipeline focuses on neurological, autoimmune diseases, and cancer, indicating a broad yet targeted approach. With notable investors such as M12 - Microsoft's Venture Fund, Playground Global, Sam Altman, Y Combinator, FoundersX Ventures, Scientia Ventures, and Accenture Ventures, 1910 Genetics has secured a strong financial backing. The most recent Venture Round investment at 31 October 2024 from Accenture Ventures signifies continued support and belief in the company's potential. Overall, 1910 Genetics appears to be a promising player in the intersection of AI, biotechnology, and healthcare, with a distinctive approach to drug discovery.